Jan 25, 2025, 16:47 | Science

Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer

Amy C. Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared…

Jan 20, 2025, 17:13 | Blog

Jarushka Naidoo: Suresh S. Ramalingam on targeted therapy for early stage NSCLC

Jarushka Naidoo, Thoracic oncologist at the Beaumont Hospital Dublin (Ireland), shared a post on X:…

Jan 17, 2025, 15:03 | Blog

Rawia Mohamed: Reflex molecular testing in cases of cholangiocarcinoma

Rawia Mohamed, Head of the Anatomical Pathology Department at Burjeel Medical City and an Associate…

Jan 15, 2025, 18:19 | Blog

Antonio Passaro: COCOON study meets primary endpoint

Antonio Passaro, Lung cancer oncologist & researcher at Instituto Europeo di Oncologia, shared a post…

Jan 9, 2025, 16:29 | Blog

Aakash Desai: Rybrevant + Lazcluze to show clinically meaningful improvement in OS vs osimertinib

Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on X: "MARIPOSA Johnson…

Jan 8, 2025, 14:07 | Science

Rami Manochakian: Results of TROPION/Lung05 Phase 2 trial are out

Rami Manochakian shared a post on X: "Hot off the press. Just published in the Journal…

Dec 29, 2024, 12:05 | Blog

Amy C. Moore: 2024 was an exciting year for lung cancer advances

Amy C. Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared…

Dec 25, 2024, 15:09 | Blog

Stephanie Saw: First line and post-progression treatment options for advanced EGFR-mutated NSCLC

Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, shared a post on X:…

Dec 22, 2024, 18:02 | Blog

Erman Akkus: Negative hyper-selection for anti-EGFR therapy in mCRC

Erman Akkus, Medical Oncology fellow at Ankara University, Faculty of Medicine, shared a post on…

Dec 17, 2024, 16:18 | Insight

Update on U.S. Regulatory Review of Subcutaneous Amivantamab

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued a…

Dec 16, 2024, 19:00 | Blog

Xiuning Le: Successful EGFR Resisters Research Summit

Xiuning Le shared a post on X: "Congrats! EGFR Resisters for the successful EGFR Resisters…

Dec 11, 2024, 17:44 | Blog

Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

Mediamedic shared a post on LinkedIn: "Editor’s Note: EGFR mutations are among the most common…

Dec 11, 2024, 13:22 | Blog

Yvonne Diaz: Bryant Lin sharing his story about his EGFR Lung Cancer diagnosis

Yvonne Diaz, Serves as EY Global Media Relations and Social Media Director, shared a post…

Dec 10, 2024, 04:30 | Blog

Texas Lung Cancer Conference 2025

Texas Lung Cancer Conference 2025 will be held from April 10-12, 2025 at Austin, Texas.…

Dec 8, 2024, 04:47 | Insight

Exciting developments in the management of unresectable stage III EGFR NSCLC

Aakash Desai, Assistant Professor and Associate Director at UAB O'Neal Comprehensive Cancer Center, shared an…

Dec 4, 2024, 14:36 | Blog

2024 Marks The 20th Anniversary of The Discovery of EGFR in NSCLC

May 2024 Marks The 20th Anniversary of the Publication of Papers on The Role of…

Dec 2, 2024, 10:22 | Blog

Tejas Patil: The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in non-small cell lung cancer

Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, posted on X about recent…

Nov 28, 2024, 12:35 | Blog

David R. Spigel: Putting the Pieces Together - Looking at Lung Cancer

David R. Spigel, Chief Scientific Officer at Sarah Cannon Research Institute, shared a post on…

Nov 27, 2024, 15:46 | Blog

Biagio Ricciuti: Discussing immunotherapy and targeted therapy for KRAS + NSCLC

Biagio Ricciuti, thoracic oncologist at the Dana-Farber Cancer Institute, shared a post on X by…

Nov 24, 2024, 15:53 | Blog

Xiuning Le: Wrapping up MaTOS24 in beautiful Lake Tahoe

Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared…

Nov 21, 2024, 12:57 | Insight

Navneet Singh: Molecular testing in all stages of NSCLC

Navneet Singh, A Thoracic Medical Oncologist and a Professor at PGIMER, shared an article on…

Nov 20, 2024, 11:30 | Insight

Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment

Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…

Nov 19, 2024, 13:43 | Insight

Highlights from New York Lung Cancers Symposium 2024 by Stephen V Liu

The New York Lung Cancers Symposium 24 (NYLung24) took place on 16th of November 2024,…

Nov 17, 2024, 07:43 | Blog

Tanja Obradovic: Important milestone for Dizal Pharmaceutical with sunvozertinib NDA submission

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…

Nov 16, 2024, 06:55 | Blog

Jill Feldman: Updated living guidelines for treating stage IV NSCLC with driver alterations

Jill Feldman, Co-Founder EGFR Resisters and a member of the programmatic panel for the Department…

Nov 9, 2024, 18:17 | Blog

Katsuaki Maehara: Using targeted NGS analysis for EGFR classical mutations in NSCLC

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “EGFR classical mutated NSCLC Frequency…

Nov 7, 2024, 11:59 | Blog

What a Stage 4 Lung Cancer Patient Looks Like with Access to Life-Saving Therapies - Young Lung Cancer Initiative

Oncogene Cancer Research shared a post by Young Lung Cancer Initiative on LinkedIn: "This is what a…

Nov 3, 2024, 14:51 | Insight

Eduard Reznik: Selection of cancer driver mutations influenced by obesity

Eduard Reznik, Assistant Attending Computational Oncologist at Memorial Sloan Kettering Cancer Center, shared a post…

Oct 24, 2024, 13:05 | Blog

Concurrent thoracic radiotherapy improves the PFS and OS with acceptable toxicity in EGFR-mutated NSCLC

Gustavo Viani shared a post on Linkedin: ''Concurrent thoracic radiotherapy improves the PFS and OS…

Oct 14, 2024, 18:04 | Blog

Time is running out to submit your abstract for the EGFR Summit - EGFR Resisters Research Summit

EGFR Resisters Research Summit shared a post on X: "TIME IS RUNNING OUT to submit your…

Oct 8, 2024, 01:55 | Blog

Giannis Mountzios: Anne-Marie Dingemans on novel approaches for EGFR and ALK positive disease

Giannis Mountzios, Medical Oncologist, 2nd Oncology Department and Clinical Trials Unit, Henary Dunant Hospital Center,…

Oct 3, 2024, 07:22 | Blog

Tanja Obradovic: AbbVie submitted telisotuzumab vedotin in adult NSCLC patients with tumors with EGFR non squamous histology

Tanja Obradovic shared a post on LinkedIn: "Completely new treatment option by novel antibody-drug conjugate (ADC)…

Sep 23, 2024, 09:48 | Insight

Heidi Ko: Alarming Biomarker Testing Gaps in NSCLC

Heidi Ko, Medical Director, Medical Affairs, Labcorp Drug Development, posted the following on LinkedIn: “These…

Sep 20, 2024, 13:27 | Blog

Stephen V Liu: FDA approved MARIPOSA2

Stephen V Liu shared on X: “FDA approved MARIPOSA2: amivantamab plus chemotherapy for EGFR NSCLC…

Sep 19, 2024, 15:36 | Blog

Xiuning Le: Busy two weeks WCLC24 and ESMO24

H. Jack West, Vice President of Clinical Development at Summit Therapeutics in Menlo Park, California, shared…

Sep 19, 2024, 11:58 | Insight

Yvonne Diaz: Treatment landscape for EGFR lung cancer

Yvonne Diaz shared on X: “Treatment landscape for EGFR lung cancer is getting more complex…

Sep 15, 2024, 16:26 | Societies

43 Posts Not To Miss From ESMO24 Day 2

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…

Sep 6, 2024, 15:44 | Insight

Jerónimo Rafael Rodríguez Cid: EGFR mutated patients doesnt have any benefit with immunotherapy in TKI's resistant tumors

Jerónimo Rafael Rodríguez Cid, Medical Oncologist in CDMX, shared a post on X: "We published…

Sep 1, 2024, 09:48 | Insight

Phase III Keynote-789 Trial of Platinum + Pemetrexed +/- Pembrolizumab in EGFR + NSCLC

Jarushka Naidoo shared a post on X: "Phase III Keynote-789 Trial of Platinum + Pemetrexed +/-Pembro…

Aug 28, 2024, 19:52 | Blog

Impact of baseline positive vs negative plasma Circulating tumor DNA for Estimated glomerular filtration rate in the FLAURA2 trial by Jonathan Riess

David Gandara, Co-Director-Center for Experimental Therapeutics, shared a post on X: "At Cal Cancer Consortium…

Aug 28, 2024, 17:09 | Blog

Tanja Obradovic: Importance of vigilant toxicity monitoring

Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…

Aug 27, 2024, 22:13 | Insight

Stephen Liu: Final anaysis of WJOG9717L

Stephen Liu shared a post on X: “Final anaysis of WJOG9717L (phase II osimertinib +/-…

Aug 27, 2024, 21:52 | Blog

David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA

David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post…

Aug 16, 2024, 12:23 | Societies

Hidehito Horinouchi summarizes some abstracts of WCLC24

Hidehito Horinouchi shared on X: Antibody Drug Conjugates in SCLC by Charlie Rudin Ifinatamab Deruxtecan…

Aug 14, 2024, 13:49 | Insight

Amol Akhade: New and exciting data coming up at WLCC 24

Amol Akhade shared on X about recent papers: "What's new and exciting data coming up…

Aug 13, 2024, 11:55 | Blog

Katsuaki Maehara: Uncommon EGFR Mutations and the variability in therapeutic efficacy

Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: "Uncommon EGFR mutations…

Aug 13, 2024, 09:57 | Blog

Zosia Piotrowska about what's next for EGFR at DCLung24

Stephen V Liu posted on X: "Dr. Zosia Piotrowska from MGH Thoracic Oncology will discuss…

Aug 12, 2024, 16:45 | Blog

Chul Kim on the advances in treating lung cancer with exon 20 or mutation at DCLung24

Stephen V Liu shared on X: "Dr. Chul Kim will discuss advances in treating lung…

Aug 12, 2024, 11:14 | Insight

Narjust Florez: Abstracts for our Presidential Symposium 2 at WCLC24

Narjust Florez shared a post on X: “Check out these abstracts for our Presidential Symposium…

Aug 11, 2024, 19:47 | Blog

Praveen Kumar Marimuthu: Phase 2 trial Carboplatin, Pemetrexed, Cetuximab for advanced NSCLC

Praveen Kumar Marimuthu, Final year Medical Oncology Trainee at CMC Vellore, shared on X: "OPEN FOR…

Aug 10, 2024, 13:45 | Insight

Katsuaki Maehara: EGFR mutated NSCLC

Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: “EGFR mutated NSCLC.…

Aug 8, 2024, 02:34 | Blog

Dr. Isabel Preeshagul will discuss perioperative targeted therapy for lung cancer at DCLung24

Stephen V Liu shared on X: “Dr. Isabel Preeshagul will discuss perioperative targeted therapy for…

Aug 6, 2024, 01:06 | Insight

Metastatic lung adenocarcinoma with EGFR and TP53 co-mutations shows mixed intra-patient tumor responses

Yüksel Ürün shared on X: "Metastatic lung adenocarcinoma with Epidermal Growth Factor Receptor (EGFR) and…

Aug 5, 2024, 14:12 | Insight

‘Meet the Expert’ session with oncology dietician Melissa Gaunt - EGFR Positive UK

EGFR Positive UK shared on X: “Eating well with EGFR positive lung cancer is so important.…

Aug 1, 2024, 15:21 | Blog

Denis Horgan: Unfortunate situation severely hampers European Union’s efforts to combat cancer

Denis Horgan, Chair at Independent Advisory Committee Chair, ICGC ARGO, shared a post on Linkedin…

Jul 30, 2024, 01:45 | Insight

TKIs with vs without upfront SRS for EGFR+ and ALK+ NSCLC and brain metastasis

Biagio Ricciuti shared on X about a recent paper by Luke Pike et al. titled…

Jul 25, 2024, 21:48 | Insight

Stephen V Liu: What is the role for SRS to brain metastases up front for EGFR or ALK NSCLC?

Stephen V Liu shared a paper by Luke R.G. Pike et al. on X, adding: “What…

Jul 25, 2024, 21:45 | Insight

Angela Mastronuzzi: Gliomatosis cerebri in children

Angela Mastronuzzi shared on LinkedIn a recent paper by Gunther Nussbaumer et al. titled "Gliomatosis…

Jul 25, 2024, 14:02 | Insight

Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?

Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on…

Jul 23, 2024, 00:16 | Blog

Research brings hope, advancing Glioblastoma treatments - Mayo Clinic

Mayo Clinic’s shared a post on LinkedIn: “Globally, approximately 300,000 people are diagnosed each year…

Jul 11, 2024, 06:37 | Insight

Results of the Complete Review on Targeted Therapies for Advanced Urothelial Carcinoma

María Natalia Gandur Quiroga shared on X: " Results and Main Messages of the Complete…

Jul 10, 2024, 09:39 | Blog

Jerónimo Rafael Rodríguez Cid: A secondary analysis from MARIPOSA

Jerónimo Rafael Rodríguez Cid, Medical Oncologist at CDMX shared a post on X: “We published…

Jul 10, 2024, 01:12 | Blog

Cancer History Project - Highlights from Lung Cancer SPORE Workshop

Cancer History Project shared on X: " Yale Cancer Center hosted the annual Lung Cancer SPORE…

Jul 8, 2024, 13:11 | Blog

New EGFR+ UK 2024 Survey Insights

EGFR Positive UK shared on X: “New EGFR+ UK 2024 Survey Insights Only 49% said…

Jul 8, 2024, 03:27 | Blog

Timely genomic testing for lung cancer - EGFR Positive UK

EGFR Positive UK shared on X: "EGFR and ROS-1 co-occurrence in lung cancer may be…

Jul 5, 2024, 06:54 | Blog

Estela Rodriguez: Underreported toxicity of myopathy from EGFR TKIs

Estela Rodriguez shared a post by Stephen V Liu, on X: "Important to study under reported toxicity…

Jul 3, 2024, 23:31 | Blog

A few papers to read about Precision oncology and use of AI suggested by Vivek Subbiah

We are presenting articles suggested by Vivek Subbiah: "1. In advanced prostate cancer, deep learning…

Jun 29, 2024, 07:45 | Insight

Katsuaki Maehara: The changes in TME and TKI treatment resistance by EGFR and ALK TKI

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: …

Jun 26, 2024, 12:40 | Societies

EGFR co-inhibition in KRAS

Megan Barnet, Medical Oncologist at The Kinghorn Cancer Centre, shared on X: "Great summary from…

Jun 25, 2024, 13:50 | Blog

Roy Herbst: Thrilled to host the lung interspore meeting

Roy Herbst, Chief of Medical Oncology at Yale University, shared a post on X: "Thrilled…

Jun 23, 2024, 10:44 | Blog

IV vs Subcutaneous amivantamab in EGFR NSCLC

Eric K. Singhi shared a post by Stephen V Liu, on X: "Absolutely agree with this! Compared with…

Jun 22, 2024, 03:29 | Insight

Triparna Sen: Celebrating 20 years of EGFR

Triparna Sen, Associate Professor at Icahn School of Medicine at Mount Sinai, posted on X: “Had…

Jun 21, 2024, 13:43 | Insight

Luca Dezzani: We are requesting approval from the U.S. FDA EGFR-mutated NSCLC therapy

Luca Dezzani, Vice President of US Oncology Medical Affairs at Johnson & Johnson, shared a…

Jun 16, 2024, 12:44 | Insight

Mara Antonoff: Dr Heather Wakelee clarifies the role of chemotherapy in NSCLC

Mara Antonoff, Associate Professor of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, shared on…

Jun 14, 2024, 03:39 | Societies

Fred R. Hirsch: Great opening of Lung SPORE meeting

Fred R. Hirsch, Director at the Center for Thoracic Oncology at Mount Sinai Hospital, shared…

Jun 13, 2024, 15:48 | Insight

Stephen Liu on a paper by Natasha Leighl, et al.

Stephen Liu recently shared a post on X: "PALOMA-3 results at Journal of Clinical Oncology…

Jun 10, 2024, 09:53 | Blog

We are proud to be members of Lung Cancer Europe - Oncogene Cancer Research

Oncogene Cancer Research recently shared a post by Lung Cancer Europe on LinkedIn, adding: "We…

Jun 1, 2024, 21:10 | Blog

LUNGevity Foundation - Subcutan injection or IV infusion for EGFR + NSCLC

LUNGevity Foundation shared a post on X: "Subcutan injection or IV infusion? Does it matter? Phas…

May 30, 2024, 11:55 | Blog

Pankaj Kumar Panda: Enriching interactive MTB webinar on First line management of EGFR mutated NSCLC

Pankaj Kumar Panda, Clinical Researcher at National Cancer Centre Singapore, shared a post on X: "Join…

May 29, 2024, 09:22 | Blog

Eric K. Singhi: Isn’t it about time we stopped saying that "patients failed treatment"

Eric K. Singhi reshared his previous post on X and added: ; "But…

May 29, 2024, 04:59 | Blog

Estela Rodriguez: Patients excluded from most clinical trials does not help us find solutions with Leptomeningeal disease

Estela Rodriguez shared a post by EGFR Resisters on X/Twitter: "Leptomeningeal disease - is one of…

May 24, 2024, 14:15 | Blog

ACS Journal Cancer Editor-in-Chief, Suresh S. Ramalingam, is sharing the primary results of the phase 3 LAURA trial at ASCO

ACS Journal Cancer shared the following on X: “Our Editor-in-Chief, Suresh S. Ramalingam, is sharing the…

May 20, 2024, 07:20 | Insight

Florez Lab: ACS Journal Cancer highlights the Florez Lab's Pregnancy and Lung Cancer Registry

Florez Lab shared a post by ACS Journal Cancer, on X "Thank you to ACS…

May 19, 2024, 14:53 | Insight

Sergio Cifuentes Canaval: KN 189 and 407 - Pooled Analysis of Outcomes

Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared on LinkedIn: "KN 189…

May 19, 2024, 05:29 | Blog

Eric Singhi: With FLAURAishing new frontline combination therapies for EGFR and metastatic NSCLC yet incomplete data

Eric Singhi shared on X: "With FLAURAishing new frontline combination therapies for EGFR and metastatic…

May 16, 2024, 16:51 | Insight

10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily

In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…

May 14, 2024, 16:28 | Blog

Christian Rolfo: Great editorial by Ticiana Batista and Suresh S. Ramalingam on 20 years of EGFR

Christian Rolfo, Associate Director Clinical Research Center of Thoracic Oncology at The Tisch Cancer Institute…

Apr 22, 2024, 13:13 | Blog

Fantastic to have our Co-founders Yvonne Diaz and Jan Clark attend BTOG24 in Belfast this week - Oncogene Cancer Research

Oncogene Cancer Research shared a post on LinkedIn: “Fantastic to have our Co-founders Yvonne Diaz…

Apr 21, 2024, 21:21 | Insight

Mainak Bardhan: Miami Cancer Institute Research Precision Oncology symposium 2nd Annual at The Ritz Carlton spearhead by one and only Manmeet Ahluwalia

Mainak Bardhan, Chief Scientific Officer, Chief of Medical Oncology and Deputy Director of Miami Cancer Institute,…

Apr 16, 2024, 20:18 | Blog

Save the Date for the 4th Annual “Living with EGFR-Mutant Lung Cancer” forum! - Dana Farber's EGFR-Mutant Lung Cancer Center

Quoting Dana Farber's EGFR-Mutant Lung Cancer Center on X/Twitter: "Save the Date: Register today for…

Apr 10, 2024, 08:56 | Career

Pasi Jänne was recently recognised with the ACS 2024 Medal of Honour Award - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared a post on LinkedIn: “Pasi Jänne, senior vice president for Translational…

Mar 31, 2024, 08:44 | Blog

UCLA Health Jonsson Comprehensive Cancer Center's presentation at the annual meeting of the American Association for Cancer Research (AACR)

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will discuss the latest breakthroughs and cutting-edge science…

Mar 26, 2024, 00:22 | Opinion

Wafik S. El-Deiry: WIN Consortium in cancer personalized medicine MTB had well over 30 participants

Wafik S. El-Deiry shared on LinkedIn: "Today’s WIN Consortium in cancer personalized medicine MTB had well…

Mar 4, 2024, 17:34 | Insight

Jill Feldman: The importance of focusing on the 3 P's when discussing treatment options after a patient experiences progression on targeted therapy

Jill Feldman, Co-Founder of EGFR Resisters, posted on LinkedIn: "It was an honor to collaborate…

Jan 16, 2024, 05:48 | Drugs

Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…

Jan 8, 2024, 14:37 | Blog

A 32-year-old lung cancer survivor, mother of 2 and oncology nurse practitioner - EGFR Resisters

EGFR Resisters shared a post on X/Twitter: "Meet Caroline, A 32-year-old lung cancer survivor, mother…

Sep 28, 2023, 19:02 | Blog

Joel Bervell: Messages like this are my reminder of how important it is to create content about healthcare disparities and how powerful spreading accurate information via social media can be.

May 14, 2023, 09:34 | Drugs

Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions - The ASCO Post

Quoting from ASCO Post, "Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging…